Xilio Therapeutics, Inc. Common Stock (XLO)
Xilio Therapeutics, Inc. is a biotechnology company focused on developing innovative immuno-oncology therapies. The company aims to harness the immune system to target and destroy cancer cells, with a pipeline centered on tumor-selective cytokine therapies. Founded to advance precision immunotherapy, Xilio aims to improve treatment outcomes for patients with solid tumors.
Company News
Xilio Therapeutics announced the closing of a $50.0 million public offering, with the potential for up to $150.0 million in total gross proceeds if all warrants are exercised. The financing was co-led by new investors Coastlands Capital and Frazier Life Sciences, and included participation from Gilead Sciences, Logos Capital, and Samsara BioCapital.
Xilio Therapeutics, a clinical-stage biotechnology company, announced a proposed public offering of pre-funded warrants, Series A, B, and C warrants to purchase shares of common stock. The company plans to use the net proceeds to advance the development of its product candidates and for general corporate purposes.
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
Here's how to size your penny stocks position The post Sizing Your Penny Stocks Position, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.